Literature DB >> 7029299

Prognostic factors in children with rhabdomyosarcoma.

E A Gehan, F N Glover, H M Maurer, W W Sutow, D M Hays, W Lawrence, W A Newton, E H Soule.   

Abstract

The characteristics of 554 evaluated patients entered into a clinical trial conducted by the Pediatric Intergroup Rhabdomyosarcoma Committee between November 1972 and September 1978 were examined for their relationship to prognosis. Prognosis was defined as disease-free time and overall survival time in clinical groups I and II and time on study and survival time in clinical groups III and IV; all times were measured from the start of treatment. The percentage of patients surviving 2 years differed significantly among the clinical groups: I, 92; II, 78; III, 64; and IV, 35. The percentage of patients free of disease at 2 years was significantly higher in group I than in group II (83 vs. 72%, respectively); P = 0.02. The patient characteristics of group I most related to disease-free and overall survival were histologic cell type (alveolar, unfavorable), lymphocyte count (low count, unfavorable), and primary site (disease in extremities, unfavorable). In group II, sex (male, favorable) and lymphocyte count (low count, unfavorable) were significantly related to disease-free and overall survival times. Patients in the clinical subgroup with both microscopic residual disease and lymph node metastasis had poorer survival than patients in other subgroups. Primary site of disease was the only characteristic of group III related to length of time on study and to survival. Orbit and the genitourinary system were favorable primary sites, whereas the retroperitoneal area and extremities were unfavorable. In group IV, primary site (genitourinary, favorable) was related to length of time on study and survival. Sex (male, favorable) was related to survival experience.

Entities:  

Mesh:

Year:  1981        PMID: 7029299

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN: 0083-1921


  7 in total

Review 1.  Soft tissue sarcomas in children.

Authors:  Gauri Kapoor; Kunal Das
Journal:  Indian J Pediatr       Date:  2011-09-21       Impact factor: 1.967

2.  Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors.

Authors:  W Lawrence; D M Hays; R Heyn; M Beltangady; H M Maurer
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

3.  Primary ophthalmic rhabdomyosarcoma in 33 patients.

Authors:  C L Shields; J A Shields; S G Honavar; H Demirci
Journal:  Trans Am Ophthalmol Soc       Date:  2001

4.  Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass.

Authors:  P Dias; B Chen; B Dilday; H Palmer; H Hosoi; S Singh; C Wu; X Li; J Thompson; D Parham; S Qualman; P Houghton
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma.

Authors:  N F Esnaola; B P Rubin; E H Baldini; N Vasudevan; G D Demetri; C D Fletcher; S Singer
Journal:  Ann Surg       Date:  2001-08       Impact factor: 12.969

6.  Orbital rhabdomyosarcoma: improved survival with combined pulsed chemotherapy and irradiation.

Authors:  S Y Ghafoor; J Dudgeon
Journal:  Br J Ophthalmol       Date:  1985-08       Impact factor: 4.638

7.  Caffeine enhancement of the effect of anticancer agents on human sarcoma cells.

Authors:  K Tomita; H Tsuchiya
Journal:  Jpn J Cancer Res       Date:  1989-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.